Skip to main content

September 2012

Job for Fresher as MR in Leading Pharma - Nemesis HRC

A leading pharma company

Post: MR

[adsense:336x280:8701650588]

CHARACTERISATION OF MARKER CHROMOSOMES

About Authors:
Masani Jigneshkumar Naranbhai
School Of Science
Biomedical Technology
Jiwaji University, Gwalior
jigneshmasani11@gmail.com

ABSTRACT
A supernumerary marker chromosome is an extra structurally abnormal chromosome of unknown origin. Various factors contribute to the difficulty of clarifying the phenotypicrisks of super numerary marker chromosomes (SMC), including differences inthe size, structure, and origin of marker chromosomes.

All marker chromosomes do not contribute the same risk of recurrence. Therefore characterization of the marker chromosomes is of utmost importance for Genetic Counseling. Different molecular techniques can be used to identify the chromosome material present in the markers. In the present retrospective data analysis of 15,000 karyotypes of all patients referred to the Center of Medical Genetics, Sir Ganga Ram Hospital from 1998 to 2012. For constitution chromosome abnormality detection, we found fifteen (0.01%) patients had presence of the SMC. Of these fifteen, eight markers had been characterized after FISH was introduced in the year 2004.  This contributed to personalized Genetic Counseling and help for future pregnancies.

Career as Clinical Research Manager in Novo Nordisk | Graduate/PG in Science, Pharmacy or Medical

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B).

Opportunity to work as Scientist I in Nektar Therapeutics | Require M.Pharm/M.Sc

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology.

Application are invited from B.Pharm, B, Sc, D.Pharm for Compounder in Lakshmibai National University of Physical Education Gwalior

Applications in prescribed form are invited from the eligible Indian Nationals for the following posts at LNUPE, Gwalior and/or its NERC, Guwahati, as indicated against them, which are however transferable anywhere in India.

Post:  Compounder 

Novo Nordisk invites for various posts as Key Accounts Executive/ Medical Representative/ Hospital Business Executives/ Sales Executives

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B).

Work as Territory Executive in Leading Multinational Pharma by krrish pharma consultants

Leading Top Multinational Pharma Company,
For medical representative jobs *urgent requirement in ‘leading top mnc pharma’ for warangal hqs & kurnool hqs of andhra pradesh.

Post: Territory Executive

[adsense:336x280:8701650588]

Application are invited for the post of Senior Research Fellow in Indian Institute of Advanced Research

Applications are invited for the position of SRF in ICMR-sponsored project: “Study of Genetic Factors Governing Multidrug Resistance in Clinical Isolates of Shigella spp.” with Dr. Ashima Bhardwaj, Assistant Professor, Department of Human Health and Diseases, IIAR.

Position : SRF (One post)

Rajendra Memorial Research Institute of Medical Sciences invites Senior Research Fellow

Rajendra Memorial Research Institute of Medical Sciences, Patna, a permanent Institute under Indian Council of Medical Research, Dept. Of Health Research, Ministry of Health & Family Welfare, Govt. Of India, invites applications from suitable Indian Nationals for appointment on the following Purely temporary posts (on contractual basis) under Intramural Project.

GLYCOGEN SYNTHASE KINASE: A DRUG TARGET IN TREATMENT OF CNS DISORDER

About Authors:
Najneen S. Shaikh1*, Mr. MAYURESH. K. RAUT2

1Sinhgad Institute of Pharmaceutical Sciences (SIPS), Lonavala
2Asst. Professor Of Phamaceutical Chemistry
Sinhgad Technical Education Society,
Kusgaon (Bk), Lonavala- 410401
*naj.pharma.23@gmail.com

ABTRACT
Glycogen synthase   kinase 3 (GSK-3) is a serine/threonine protein kinase, that mediates the addition of phosphate molecules on certain serine and threonine amino acids in particular cellular substrates.
Glycogen synthase kinase-3 (GSK3) has recently been linked to mood disorders and schizophrenia, and the neurotransmitter systems and therapeutic treatments associated with these diseases. GSK3 is a widely influential enzyme that is capable of phosphorylating, and thereby regulating, over forty known substrates. Four mechanisms regulating GSK3 (phosphorylation, protein complexes, localization, and substrate phosphorylation) combine to provide substrate-specific regulation of the actions of GSK3. Several intracellular signaling cascades converge on GSK3 to modulate its activity, and several neurotransmitter systems also regulate GSK3, including serotonergic, dopaminergic, cholinergic, and glutamatergic systems. Because of changes in these neurotransmitter systems and the actions of therapeutic drugs, GSK3 has been linked to the mood disorders, bipolar disorder and depression, and to schizophrenia.

[adsense:336x280:8701650588]